Loading...
*  Philadelphia chromosome
"Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia". British Journal of ... Kurzrock, R.; Kantarjian, H. M.; Druker, B. J.; Talpaz, M. (2003). "Philadelphia chromosome-positive leukemias: From basic ... The ABL tyrosine kinase activity of BCR-Abl is elevated relative to wild-type ABL. Since ABL activates a number of cell cycle- ... Chronic myelogenous leukemia Wapner J. The Philadelphia Chromosome: A Genetic Mystery, a Lethal Cancer, and the Improbable ...
*  Drug design
... designed specifically for the bcr-abl fusion protein that is characteristic for Philadelphia chromosome-positive leukemias ( ... chronic myelogenous leukemia and occasionally acute lymphocytic leukemia). Imatinib is substantially different from previous ... 5-HT3 antagonists Acetylcholine receptor agonists Angiotensin receptor antagonists Bcr-Abl tyrosine-kinase inhibitors ...
*  K562 cells
"Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome", Blood, 45 (3): 321-34, PMID 163658 Drexler ... presumably due to the downregulation of surface adhesion molecules by bcr:abl. However, another study suggests that bcr:abl ... The cells are non-adherent and rounded, are positive for the bcr:abl fusion gene, and bear some proteomic resemblance to both ... K562 cells are of the erythroleukemia type, and the line is derived from a 53-year-old female chronic myelogenous leukemia ...
*  STAT5
"Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia". Oncogene. 13 (2): 247-54. PMID ... "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells". Nat. Med. 2 (5): 561-6. ... Different inhibitors have been designed to target different kinases: inhibition of BCR/ABl constitutes the basis of the ... Leukemia. 23 (8): 1441-5. doi:10.1038/leu.2009.50. PMID 19295546. Behbod F, Nagy ZS, Stepkowski SM, Karras J, Johnson CR, ...
*  Imatinib
Schiffer CA (July 2007). "BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia". N. Engl. J. Med. 357 (3): 258- ... it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that is Philadelphia chromosome-positive ... In chronic myelogenous leukemia, the Philadelphia chromosome leads to a fusion protein of abl with bcr (breakpoint cluster ... "Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase". Nat. Med. ...
*  Chronic myelogenous leukemia
"Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL ... 2012 and 27 March 2013 respectively for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic ... Chronic myelogenous leukemia (CML) is a cancer of the white blood cells. It is a form of leukemia characterized by the ... This means that a little over 10% of all newly diagnosed leukemia cases will be chronic myelogenous leukemia. The average risk ...
*  KBM-7 cells
... are a Chronic myelogenous leukemia (CML) cell line used for biomedical research. Like all cancer cell lines, it is ... Like other CML cells lines (e.g., K562) KBM-7 cells are positive for the Philadelphia chromosome harboring the BCR-ABL ... "Ph-positive chronic myeloid leukemia with near-haploid conversion in vivo and establishment of a continuously growing cell line ... KBM-7 cells were derived from a 39-year-old man with chronic myeloid leukemia in blast crisis. The original cell line contained ...
*  Cancer biomarkers
BCR-ABL (Chronic Myeloid Leukemia), BRCA1 / BRCA2 (Breast/Ovarian Cancer), BRAF V600E (Melanoma/Colorectal Cancer), CA-125 ( ... BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia". Blood. 117 ... For instance, in the 1960s, researchers discovered the majority of patients with chronic myelogenous leukemia possessed a ... For many years, the BCR-ABL was simply used as a biomarker to stratify a certain subtype of leukemia. However, drug developers ...
*  Dasatinib
... is used to treat people with chronic myeloid leukemia and people with acute lymphoblastic leukemia who are positive ... It is a tyrosine kinase inhibitor and works by blocking a number of tyrosine kinases such as Bcr-Abl and the Src kinase family ... is a chemotherapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia ... The main targets of dasatinib are BCR/Abl (the "Philadelphia chromosome"), Src, c-Kit, ephrin receptors, and several other ...
*  Bcr-Abl tyrosine-kinase inhibitor
... s (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). ... "BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review". ... Bcr-Abl dependent mechanisms include over expression or amplification of the Bcr-Abl gene and point mutations within the Bcr- ... Bcr) gene at chromosome 22, resulting in a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that ...
*  Nilotinib
"FDA Approves Tasigna for Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia". U.S. Food and Drug ... Nilotinib is a selective Bcr-Abl kinase inhibitor that is 10-30 fold more potent than imatinib in inhibiting Bcr-Abl tyrosine ... positive chronic myelogenous leukaemia. The drug carries a black box warning for possible heart complications. In June 2006, a ... Nilotinib inhibits the kinases BCR-ABL, KIT, LCK, EPHA3, EPHA8, DDR1, DDR2, PDGFRB, MAPK11 and ZAK. Bcr-Abl tyrosine-kinase ...
*  International Classification of Diseases for Oncology
BCR/ABL positive)/(Ph1 positive)/t(9;22)(q34;q11) M9876/3 Atypical chronic myelogenous leukemia BCR/ABL negative Atypical ... NOS M9875/3 Chronic myelogenous leukemia BCR/ABL positive Philadelphia chromosome (Ph1 positive) t(9;22)(q34;q11) Chronic ... NOS Chronic myelogenous leukemia, NOS Chronic granulocytic leukemia, NOS Chronic myelocytic leukemia, NOS M9866/3 Acute ... Chronic lymphocytic leukemia Chronic lymphoid leukemia Chronic lymphatic leukemia M9826/3 Burkitt cell Leukemia (see also M9687 ...
*  ABL (gene)
... a characteristic abnormality in chronic myelogenous leukemia (CML) and rarely in some other leukemia forms. The BCR-ABL ... "Interaction of BCR-ABL with the retinoblastoma protein in Philadelphia chromosome-positive cell lines". Int. J. Hematol. 65 (2 ... Second generation BCR-ABL tyrosine-kinase inhibitors are also under development to inhibit BCR-ABL mutants resistant to ... "Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr". Cancer Res. 63 (2): 298-303. PMID 12543778. ...
*  Bosutinib
"Bosulif Approved for Previously Treated Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia". 5 Sep 2012. "Bosulif : ... It is an ATP-competitive Bcr-Abl tyrosine-kinase inhibitor with an additional inhibitory effect on SRc family kinases ( ... in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib ... chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy. Adverse effects by incidence:Very common ...
*  Ponatinib
... a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based ... Subsequent studies of 449 patients treated during 4 years with ponatinib for chronic phase chronic myelogenous leukemia found ... Approval was also granted for T315I-positive and T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia. ... The substance potently inhibits, on nanomolar scale, Src and Bcr-Abl kinases including many common imatinib resistant Bcr-Abl ...
*  Tyrosine-kinase inhibitor
"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells". Nat Med. 2 (5): 561-6. ... Based on this work imatinib was developed against chronic myelogenous leukemia (CML) and later gefitinib and erlotinib aiming ... For example, they have substantially improved outcomes in chronic myelogenous leukemia. They are also called tyrphostins, the ... Bcr-Abl tyrosine-kinase inhibitor Protein kinase inhibitor Yaish P, Gazit A, Gilon C, Levitzki A (1988). "Blocking of EGF- ...
*  Exosome component 2
1989). "Structural alterations of the BCR and ABL genes in Ph1 positive acute leukemias with rearrangements in the BCR gene ... in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia". Mol ... "A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia". Leukemia. 4 (6 ... 1987). "The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript". Mol. ...
*  Carcinogenesis
... which occurs in chronic myelogenous leukemia, and results in production of the BCR-abl fusion protein, an oncogenic tyrosine ... First, there exists a highly positive correlation (Spearman's rho = 0.81; P < 3.5 × 10−8) between the risk of developing cancer ... and miR-29b in chronic lymphocytic leukemia". Blood. 119 (5): 1162-72. doi:10.1182/blood-2011-05-351510. PMC 3277352 . PMID ... Samaras V, Rafailidis PI, Mourtzoukou EG, Peppas G, Falagas ME (June 2010). "Chronic bacterial and parasitic infections and ...
*  Musashi rna binding protein 2
In both of chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML), MSI2 regulates hematopoietic steam cell ... It has been found that MSI2 participates together with BCR-ABL gene to stimulate the progress to the aggressive phase. The ... positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22". Haematologica. 93 (12): 1903-7. ... Chronic myelogenous leukemia (CML) progresses from the initial phase, where differentiated myeloid cells are accumulated, to ...
*  Gastrointestinal stromal tumor
Imatinib (Glivec/Gleevec), an orally administered drug initially marketed for chronic myelogenous leukemia based on bcr-abl ... In the gut, however, a mass staining positive for CD117 is likely to be a GIST, arising from ICC cells. The c-KIT molecule ... of all GISTs are CD117-positive (other possible markers include CD34, DOG-1, desmin, and vimentin). Other cells that show CD117 ...
*  GAB2
In chronic myelogenous leukemia (CML), GAB2 interacts with the Bcr-Abl complex and is instrumental in maintaining the oncogenic ... By binding to the p85 subunit of PI3K, and continuing this signaling pathway GAB provides positive feedback for the creation of ... The Grb2/GAB2 complex is recruited to phosphorylated Y177 of the Bcr-Abl complex leading to Bcr-Abl-mediated transformation and ... "Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2". ...
*  BCR (gene)
... "e19a2-positive chronic myeloid leukaemia with BCR exon e16-deleted transcripts". Leukemia. 16 (8): 1562-3. doi:10.1038/sj.leu. ... The Bcr-Abl oncoprotein oligomerisation domain found at the N-terminus of BCR is essential for the oncogenicity of the BCR-ABL ... which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is ... Kolibaba KS, Bhat A, Heaney C, Oda T, Druker BJ (March 1999). "CRKL binding to BCR-ABL and BCR-ABL transformation". Leuk. ...
*  ETV6
... acute lymphocytic leukemia (ALL), Philadelphia chromosome negative chronic myelogenous leukemia (Ph(-)CML), myelodysplastic ... "Nucleotide sequence analysis of human abl and bcr-abl cDNAs". Oncogene. 4 (12): 1477-81. PMID 2687768. Buijs A, Sherr S, van ... "Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3". Blood ... chronic myelomonocytic leukemia, acute myelocytic leukemia, B cell acute lymphoblastic leukemia, mixed phenotype acute leukemia ...
*  Clonal hypereosinophilia
BCR-ABL1 fusion gene responsible for Philadelphia chromosome positive chronic myelogenous leukemia and chronic lymphocytic ... Khatri A, Wang J, Pendergast AM (2016). "Multifunctional Abl kinases in health and disease". Journal of Cell Science. 129 (1): ... atypical chronic myelogenous leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome, acute myelogenous leukemia, ... chronic myelogenous leukemias; or chronic myelomonocytic leukemia with involvement of tonsils. Some of these patients may ...
*  Targeted therapy
... affinity for the oncofusion protein BCR-Abl which is a strong driver of tumorigenesis in chronic myelogenous leukemia. Although ... in patients with LHRH receptor-positive platinum resistant ovarian cancer". 2010. [American Association for Cancer Research " ... Imatinib mesylate (Gleevec, also known as STI-571) is approved for chronic myelogenous leukemia, gastrointestinal stromal tumor ... Gleevec is most effective targeting BCR-Abl. Other examples of molecular targeted therapeutics targeting mutated oncogenes, ...
*  Cancer
Another common example is the class of Bcr-Abl inhibitors, which are used to treat chronic myelogenous leukemia (CML). ... How the Relentless Promotion of Positive Thinking Has Undermined America. Henry Holt and Company. pp. 15-44. ISBN 978-0-8050- ... which occurs in chronic myelogenous leukemia and results in production of the BCR-abl fusion protein, an oncogenic tyrosine ... and human T-cell leukemia virus-1 (T-cell leukemias). Bacterial infection may also increase the risk of cancer, as seen in ...